================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) May 20, 2004 (May 19, 2004)
------------
Pharmion Corporation
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-50447 84-1521333
- ---------------------------- ---------------- -------------------
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
2525 28th Street, Boulder, Colorado 80301
- ---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 720-564-9100
-------------
- --------------------------------------------------------------------------------
(Former name or former address if changed since last report)
================================================================================
Item 5. Other Events and Regulation FD Disclosure
On May 19, 2004, Pharmion Corporation, a Delaware corporation (the
"Company"), issued a press release announcing that the Company is
expanding its data package for EMEA application for Thalidomide
Pharmion(TM) and resubmitting for multiple myeloma. The press
release is attached hereto as Exhibit 99.1 and incorporated herein
by reference.
Item 7. Financial Statements, Pro Forma Financial Information And Exhibits
(c) Exhibits
99.1 Press Release, dated May 19, 2004, entitled "Pharmion to Expand
Data Package for EMEA Application for Thalidomide Pharmion(TM) and
Resubmit for Multiple Myeloma."
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMION CORPORATION
Date: May 20, 2004 By: /s/ Erle T. Mast
-----------------------
Erle T. Mast
Chief Financial Officer
2